Whole Plasmid Sequencing Market : Global Industry Analysis and Opportunity Assessment, 2036

Whole Plasmid Sequencing Market Size, Market Forecast and Outlook By FMI

Summary of the Whole Plasmid Sequencing Market

• Demand and Growth Drivers
  • Growth in gene therapy and mRNA vaccine manufacturing is likely to sustain demand for whole plasmid sequencing services that verify vector integrity and sequence accuracy in biopharmaceutical production.
  • Regulatory requirements for complete plasmid characterization in biologic drug submissions are expected to increase procurement of whole plasmid sequencing from CDMOs and CROs during the forecast period.
  • Advancement in long-read sequencing technology is likely to reduce per-plasmid sequencing costs and expand adoption across smaller biotech companies through 2036.
• Product and Segment View
  • Direct oral anticoagulants (DOACs) is likely to account for 39.1% of the drug class segment, reflecting sustained procurement across primary end-use categories.
  • Venous thromboembolism (VTE) is likely to account for 34.7% of the application segment, reflecting sustained procurement across primary end-use categories.
  • Hospitals is likely to account for 61.8% of the end user segment, reflecting sustained procurement across primary end-use categories.
• Geography and Competitive Outlook
  • China is likely to remain a key market at 18.4%, supported by rapid biopharmaceutical manufacturing expansion.
  • India is likely to sustain growth at 17.0%, driven by expanding pharmaceutical manufacturing capacity.
  • Companies that combine product breadth with customer access and distribution reach are likely to strengthen competitive positioning during the forecast period.
• Analyst Opinion
  • Nandini Roy Choudhury, Principal Consultant at FMI says, 'The whole plasmid sequencing market reflects biopharmaceutical quality control requirements and gene therapy manufacturing growth. Service providers that can deliver rapid, cost-effective, and regulatory-compliant whole plasmid characterization are positioned to capture long-term pharmaceutical accounts during the forecast period.'
  • The whole plasmid sequencing market is evolving from research-grade service toward regulatory-compliant pharmaceutical quality control.
  • Adoption is increasing due to gene therapy manufacturing growth and regulatory requirements for complete vector characterization.
  • Demand is further supported by long-read sequencing cost reduction expanding access for smaller biotech companies.
  • Service providers with validated workflows, regulatory expertise, and rapid turnaround are likely to capture pharmaceutical accounts.

Whole Plasmid Sequencing Market Definition

The whole plasmid sequencing market includes sequencing services and platforms that provide complete, end-to-end characterization of circular plasmid DNA molecules used in biopharmaceutical manufacturing, gene therapy vector production, vaccine development, and recombinant protein expression systems.

Whole Plasmid Sequencing Market Inclusions

Market scope encompasses all commercially traded whole plasmid sequencing products and services categorized by service type (sequencing and analysis, library preparation, data interpretation), technology (long-read sequencing, short-read assembly, hybrid approaches), end user (biopharmaceutical companies, CROs and CDMOs, academic research institutions), application (gene therapy QC, vaccine manufacturing, recombinant protein production, synthetic biology), and delivery model (service-based, platform licensing). The range of revenue sizes is from 2026 to 2036.

Whole Plasmid Sequencing Market Exclusions

The scope does not include general whole-genome sequencing, targeted gene panel sequencing, or RNA sequencing services not specifically designed for circular plasmid DNA characterization.

Whole Plasmid Sequencing Market Research Methodology

• Primary Research: FMI analysts conducted interviews with manufacturers, end-use procurement teams, and distribution partners across key markets.
• Desk Research: Combined data from industry associations, regulatory filings, trade publications, and manufacturer disclosures.
• Market sizing and forecasting: Bottom-up aggregation across product types, end-use applications, and regional adoption curves, validated against industry benchmarks.
• Data validation: Cross-checked every quarter against production data, trade statistics, and manufacturer-reported figures.

Why is the Whole Plasmid Sequencing Market Growing?

• Gene therapy and vaccine manufacturing growth are creating sustained demand for whole plasmid sequencing services that verify vector integrity and sequence fidelity in biopharmaceutical production.
• Regulatory requirements for complete plasmid characterization in biologic drug filings are increasing outsourcing of sequencing services to specialized providers.
• China (18.4%) and India (17.0%) lead growth, reflecting expanding biopharmaceutical manufacturing capacity and growing adoption of quality control sequencing protocols.

The whole plasmid sequencing market is expanding at 6.9% CAGR, reflecting biopharmaceutical quality control demand, gene therapy manufacturing growth, and long-read sequencing technology advancement. Sequencing services and analysis account for the primary revenue stream as biopharmaceutical companies outsource plasmid characterization to specialized sequencing providers with validated workflows.

Gene therapy vector manufacturing represents the highest-growth application, where regulatory submissions require complete sequence verification of plasmid DNA used for viral vector production. Each gene therapy program in clinical development or commercial manufacturing requires ongoing plasmid sequencing for batch release and stability monitoring.

Long-read sequencing platforms from providers like Oxford Nanopore and Pacific Biosciences enable complete plasmid reads in single passes, eliminating assembly artifacts and providing higher confidence in sequence accuracy compared to short-read approaches. Cost reduction in long-read sequencing is expanding adoption from large pharma to mid-size biotech companies.

Market Segmentation Analysis

• Direct oral anticoagulants (DOACs) accounts for 39.1% of the drug class segment, reflecting consistent demand across primary applications.
• Venous thromboembolism (VTE) accounts for 34.7% of the application segment, reflecting consistent demand across primary applications.
• Hospitals accounts for 61.8% of the end user segment, reflecting consistent demand across primary applications.

The whole plasmid sequencing market is segmented by drug class, application, end user, product.

Insights into the Direct oral anticoagulants (DOACs) Drug Class Segment

In 2026, direct oral anticoagulants (doacs) is expected to account for 39.1% of the drug class segment. Demand reflects procurement preferences where performance and specification compliance are critical.

Competitive positioning depends on production capability, quality certification, and the ability to meet evolving requirements. Suppliers with established relationships and proven performance are likely to maintain share.

Insights into the Venous thromboembolism (VTE) Application Segment

In 2026, venous thromboembolism (vte) is expected to account for 34.7% of the application segment. Demand reflects procurement preferences where performance and specification compliance are critical.

Competitive positioning depends on production capability, quality certification, and the ability to meet evolving requirements. Suppliers with established relationships and proven performance are likely to maintain share.

Whole Plasmid Sequencing Market Drivers, Restraints, and Opportunities

• Gene therapy manufacturing growth and regulatory requirements for complete plasmid characterization are creating sustained demand for whole plasmid sequencing services.
• Sequencing cost per plasmid and turnaround time constraints limit adoption among cost-sensitive academic and early-stage biotech clients.
• Long-read sequencing technology advancement is reducing per-plasmid costs and expanding the addressable market for routine quality control sequencing.

The whole plasmid sequencing market reflects biopharmaceutical quality control requirements, gene therapy manufacturing growth, and sequencing technology advancement.

Gene Therapy and Vaccine Manufacturing QC Demand

Biopharmaceutical companies require complete plasmid sequence verification for regulatory submissions and batch release. Gene therapy programs in clinical and commercial stages create recurring sequencing demand for each manufacturing campaign.

Sequencing Cost and Throughput Limitations

Per-plasmid sequencing costs and laboratory turnaround times influence adoption velocity. Service providers that can deliver rapid, cost-effective whole plasmid sequencing gain competitive advantage in high-volume pharmaceutical accounts.

Long-Read Technology Cost Reduction

Advancement in nanopore and single-molecule sequencing is reducing per-read costs and enabling single-pass complete plasmid sequencing. Cost reduction expands adoption from large pharmaceutical to mid-size biotech and academic clients.

Analysis of Whole Plasmid Sequencing Market By Key Countries

Country	CAGR
China	18.4%
India	17.0%
Germany	15.7%
Brazil	14.3%
USA	12.9%
UK	11.6%
Japan	10.2%

• China leads with 18.4%, supported by rapid biopharmaceutical manufacturing expansion.
• India at 17.0%, reflecting expanding pharmaceutical manufacturing capacity.
• Germany at 15.7%, reflecting advanced biopharmaceutical manufacturing.

The global whole plasmid sequencing market is expected to grow at a rate of 6.9% per year from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for Whole Plasmid Sequencing Market in China

China is expected to grow at 18.4% through 2036, reflecting rapid biopharmaceutical manufacturing expansion, gene therapy development programs, and growing adoption of sequencing-based quality control.

• Biopharma expansion drives sequencing demand.
• Gene therapy development increases plasmid QC needs.
• Manufacturing growth sustains service procurement.

Future Outlook for Whole Plasmid Sequencing Market in India

India is expected to grow at 17.0% through 2036, reflecting expanding pharmaceutical manufacturing capacity, growing biosimilar production, and increasing adoption of advanced quality control technologies.

• Pharma manufacturing growth creates QC demand.
• Biosimilar production increases sequencing needs.
• Technology adoption accelerates service procurement.

Opportunity Analysis of Whole Plasmid Sequencing Market in Germany

Germany is expected to grow at 15.7% through 2036, reflecting advanced biopharmaceutical manufacturing, strict regulatory compliance, and leadership in pharmaceutical quality control standards.

• Advanced manufacturing sustains QC sequencing demand.
• Regulatory compliance drives characterization requirements.
• Quality standards support premium service procurement.

In-depth Analysis of Whole Plasmid Sequencing Market in Brazil

Brazil is expected to grow at 14.3% through 2036, reflecting pharmaceutical manufacturing growth, biologics production expansion, and increasing adoption of molecular quality control.

• Pharma growth creates quality control demand.
• Biologics expansion increases sequencing needs.
• Technology adoption supports service procurement.

Sales Analysis of Whole Plasmid Sequencing Market in USA

USA is expected to grow at 12.9% through 2036, reflecting largest biopharmaceutical market, gene therapy manufacturing leadership, and established sequencing service provider infrastructure.

• Largest biopharma market sustains sequencing demand.
• Gene therapy leadership drives plasmid QC volumes.
• Established service infrastructure supports adoption.

Growth Analysis of Whole Plasmid Sequencing Market in UK

UK is expected to grow at 11.6% through 2036, reflecting biopharmaceutical R&D strength, MHRA regulatory requirements, and growing gene therapy development activity.

• Biopharma R&D strength drives sequencing demand.
• Regulatory requirements sustain QC procurement.
• Gene therapy growth increases characterization needs.

Market Outlook for Whole Plasmid Sequencing Market in Japan

Japan is expected to grow at 10.2% through 2036, reflecting advanced pharmaceutical manufacturing, precision quality standards, and growing adoption of sequencing-based characterization.

• Advanced manufacturing sustains precision QC demand.
• Quality standards drive sequencing specification.
• Technology adoption supports service procurement.

Competitive Landscape and Strategic Positioning

• Johnson & Johnson and Boehringer Ingelheim GmbH lead through broad portfolios and established customer relationships.
• Mid-tier participants compete through regional specialization and targeted product development.
• New entrants focus on technology-differentiated products and specialized applications.

Johnson & Johnson holds a strong position through technology leadership and established relationships. Boehringer Ingelheim GmbH competes through complementary capabilities.

Sanofi SA and Pfizer Inc. maintain positions through specialized offerings.

Barriers include established relationships, regulatory requirements, technology expertise, and manufacturing scale. Strategic priorities include technology advancement, compliance, and geographic expansion.

Key Companies in the Whole Plasmid Sequencing Market

Key global companies leading the whole plasmid sequencing market include:

• Johnson & Johnson, Boehringer Ingelheim GmbH, Sanofi SA hold leading positions through technology leadership and established relationships.
• Pfizer Inc., Bayer AG have established positions through specialized offerings.
• Plasmidsaurus Inc., Eurofins Genomics, Azenta Life Sciences represent emerging participants with growth potential.

Competitive Benchmarking: Whole Plasmid Sequencing Market

Company	Sequencing Technology	Throughput Capacity	Regulatory Expertise	Geographic Reach
Johnson & Johnson	High	High	High	Global
Boehringer Ingelheim GmbH	High	Medium	High	Global
Sanofi SA	Medium	Medium	Medium	Global
Pfizer Inc.	Medium	Moderate	Medium	Regional
Bayer AG	Moderate	Moderate	Moderate	Regional
Bristol-Myers Squibb	Moderate	Low	Moderate	Regional
Plasmidsaurus Inc.	Low	Low	Low	Niche
Eurofins Genomics	Low	Low	Low	Niche
Azenta Life Sciences	Low	Low	Low	Niche
Genewiz (Azenta)	Low	Low	Low	Niche

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Whole Plasmid Sequencing Market

• In 2025, Thermo Fisher Scientific expanded its whole plasmid sequencing service capacity to address growing demand from gene therapy and vaccine manufacturers requiring complete vector characterization.
• In 2025, a leading sequencing provider launched a rapid-turnaround whole plasmid sequencing service targeting biopharmaceutical batch release and stability testing applications.

Key Players in the Whole Plasmid Sequencing Market

Major Global Players

• Johnson & Johnson
• Boehringer Ingelheim GmbH
• Sanofi SA
• Pfizer Inc.
• Bayer AG
• Bristol-Myers Squibb
• AstraZeneca

Emerging Players/Startups

• Plasmidsaurus Inc.
• Eurofins Genomics
• Azenta Life Sciences
• Genewiz (Azenta)
• Eton Bioscience

Report Scope and Coverage

Metric	Value
Quantitative Units	USD 5.17 Billion to USD 10.08 Billion, at a CAGR of 6.9%
Market Definition	The whole plasmid sequencing market encompasses whole plasmid DNA sequencing services and platforms used for complete vector characterization in gene therapy, vaccine, and recombinant protein biopharmaceutical manufacturing quality control.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	China, India, Germany, Brazil, USA, UK, Japan, 30 plus countries
Key Companies Profiled	Johnson & Johnson, Boehringer Ingelheim GmbH, Sanofi SA, Pfizer Inc., Bayer AG, Bristol-Myers Squibb, AstraZeneca, Sun Pharmaceutical Industries, Daiichi Sankyo, Portola Pharmaceuticals, Laurus Labs
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Segmentation

Whole Plasmid Sequencing Market Segmented by Drug Class:

• Direct oral anticoagulants (DOACs)
• Low molecular weight heparins (LMWHs)
• Vitamin k antagonists (VKAs)
• Factor Xa inhibitors
• Anticoagulants
• Antiplatelet agents

Whole Plasmid Sequencing Market Segmented by Application:

• Venous thromboembolism (VTE)
• Atrial fibrillation (AF) and stroke prevention
• Post-surgical prophylaxis
• Cancer-associated thrombosis (CAT)
• Pregnancy-associated thrombosis
• Thromboprophylaxis in cardiovascular diseases
• Others

Whole Plasmid Sequencing Market Segmented by End User:

• Hospitals
• Ambulatory surgical centers (ASCs)
• Clinics
• Home care settings
• Specialty pharmacies

Whole Plasmid Sequencing Market Segmented by Product:

• Sequencing Services
  • Short Read Sequencing Services
    • Illumina Based Sequencing
    • Ion Semiconductor Sequencing
  • Long Read Sequencing Services
    • Nanopore Sequencing
    • Single Molecule Real Time Sequencing
• Sequencing Kits And Reagents
  • Library Preparation Kits
    • Fragmentation Kits
    • Adapter Ligation Kits
  • Sequencing Reagents
    • Polymerase Reagents
    • Buffer Solutions
• Instruments
  • Benchtop Sequencers
    • Low Throughput Systems
    • Medium Throughput Systems
  • High Throughput Sequencers
    • Core Lab Systems
    • Production Scale Systems

Whole Plasmid Sequencing Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• USA Food and Drug Administration. (2024). FDA Guidance on Chemistry, Manufacturing, and Controls for Gene Therapy Products. FDA.
• European Medicines Agency. (2024). EMA Guidelines on Quality Requirements for Plasmid DNA Vectors. EMA.
• International Council for Harmonisation. (2024). ICH Q5B: Quality of Biotechnological Products, Analysis of Expression Construct. ICH.
• World Health Organization. (2024). WHO Technical Report on Gene Therapy Product Quality Standards. WHO.
• International Organization for Standardization. (2024). ISO 20395: Biotechnology, Requirements for Evaluating Performance of Quantification Methods for Nucleic Acid Sequences. ISO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the size of the market and revenue from 2026 to 2036.
• Segmentation analysis across all product, application, and end-use categories.
• Regional insights covering more than 30 markets worldwide.
• Technology and material analysis relevant to market applications.
• Competitive landscape assessment including company benchmarking.
• Identification of investment opportunities across high-growth segments and regions.
• Supply chain analysis and distribution channel assessment.
• Data delivery in PDF and Excel formats.